A study to assess the usefulness of using genetics to improve prescribing

Not Applicable

• Conditions: Pre-emptive pharmacogenetic testing; Not Applicable

• Registration Number: ISRCTN14050335
• Lead Sponsor: niversity of Manchester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-23
• Last Update Posted: 22 April 2024
• Study Completion: 2024-10-04

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 646

Inclusion Criteria

1. Participants must be admitted to the Manchester University NHS Foundation Trust or attend an outpatient appointment, as a patient or relative, at the Manchester University NHS Foundation Trust
2. Participants must have the capacity to independently consent
3. Patients must be over the age of 18 years

Exclusion Criteria

1. Patients unable to independently consent
2. Patients under the age of 18 years

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of patients with an actionable genotype related to a medicine they are currently, or have previously been, prescribed. Genotype-phenotype relationships will be assigned where there is high-level PharmGKB evidence for clinical actionability (Levels 1A or 1B). This will be expressed as a percentage of the whole study cohort (i.e. number of individuals with an actionable variant receiving a corresponding medicine/the total study cohort). Sub analyses will be undertaken by age and comorbid state. For the inpatient cohort (IPTIP-I) hospital prescriptions will be assessed at a single timepoint during the admission following recruitment. For both cohorts (IPTIP-I and IPTIP-O), Historical GP medicine records will be accessed at a single timepoint after recruitment has closed. Genetic data will be generated for all participants once recruitment has closed.